FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *
   Oosthuizen Johannes Jacobus
   (Last) (First) (Middle)
   MERCK & CO., INC., 2000 GALLOPING HILL ROAD
   KENILWORTH, NJ 07033

2. Date of Event Requiring Statement (MM/DD/YYYY)
   2/28/2022

3. Issuer Name and Ticker or Trading Symbol
   Merck & Co., Inc. [MRK]

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
   ___ Director
   ___ 10% Owner
   ___ Officer (give title below)
   X SVP, U.S. Market /

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)
   X Form filed by One Reporting Person
   ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security</th>
<th>Amount of Securities Beneficially Owned</th>
<th>Ownership Form: Direct (D) or Indirect (I)</th>
<th>Nature of Indirect Beneficial Ownership</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>13222.881</td>
<td>D</td>
<td></td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>Title of Derivate Security</th>
<th>Date Exercisable and Expiration Date (MM/DD/YYYY)</th>
<th>Title and Amount of Securities Underlying Derivative Security</th>
<th>Conversion or Exercise Price of Derivative Security</th>
<th>Ownership Form of Derivative Security: Direct (D) or Indirect (I)</th>
<th>Nature of Indirect Beneficial Ownership</th>
</tr>
</thead>
<tbody>
<tr>
<td>Restricted Stock Unit</td>
<td>5/3/2020 (1) 5/3/2022</td>
<td>Common Stock 773</td>
<td></td>
<td>(2)</td>
<td>D</td>
</tr>
<tr>
<td>Restricted Stock Unit</td>
<td>5/1/2021 (3) 5/1/2023</td>
<td>Common Stock 1732</td>
<td></td>
<td>(2)</td>
<td>D</td>
</tr>
<tr>
<td>Restricted Stock Unit</td>
<td>10/30/2021 (4) 10/30/2023</td>
<td>Common Stock 1828</td>
<td></td>
<td>(2)</td>
<td>D</td>
</tr>
<tr>
<td>Restricted Stock Unit</td>
<td>2/8/2023 (6) 2/8/2025</td>
<td>Common Stock 13002</td>
<td></td>
<td>(2)</td>
<td>D</td>
</tr>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>5/5/2018 (7) 5/4/2027</td>
<td>Common Stock 14703</td>
<td>$62.07</td>
<td>(2)</td>
<td>D</td>
</tr>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>5/3/2020 (8) 5/2/2029</td>
<td>Common Stock 17455</td>
<td>$77.62</td>
<td>(2)</td>
<td>D</td>
</tr>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>5/1/2021 (9) 4/30/2030</td>
<td>Common Stock 20313</td>
<td>$75.36</td>
<td>(2)</td>
<td>D</td>
</tr>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>5/4/2022 (10) 5/3/2031</td>
<td>Common Stock 21139</td>
<td>$73.73</td>
<td>(2)</td>
<td>D</td>
</tr>
</tbody>
</table>
Explanation of Responses:

(1) These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022.

(2) Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

(3) These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.

(4) These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 10/30/2021, 10/30/2022 and 10/30/2023.

(5) These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.

(6) These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 2/8/2023, 2/8/2024 and 2/8/2025.


Remarks:
See Exhibit 24 - Power of Attorney

Reporting Owners

<table>
<thead>
<tr>
<th>Reporting Owner Name / Address</th>
<th>Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oosthuizen Johannes Jacobus</td>
<td></td>
</tr>
<tr>
<td>MERCK &amp; CO., INC.</td>
<td></td>
</tr>
<tr>
<td>2000 GALLOPING HILL ROAD</td>
<td></td>
</tr>
<tr>
<td>KENILWORTH, NJ 07033</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Director</td>
</tr>
<tr>
<td></td>
<td>10% Owner</td>
</tr>
<tr>
<td></td>
<td>Officer</td>
</tr>
<tr>
<td></td>
<td>SVP, U.S. Market</td>
</tr>
</tbody>
</table>

Signatures

/s/ Kelly E. W. Grez, as attorney-in-fact for Johannes Oosthuizen

Date 3/10/2022

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Jennifer Zachary, Jon Filderman, Kelly Grez, and Anthony Wildasin signing singly, the undersigned?s true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer or director of Merck & Co., Inc. (the ?Company?), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Forms 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact?s discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact?s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned?s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned?s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. This Power of Attorney revokes all previous powers of attorney with respect to the subject matter of this Power of Attorney.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 28th day of February 2022.

/s/ Johannes Oosthuizen
Johannes Oosthuizen